Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalteparin in Recurrent Pregnancy Loss (ETHIG II)
NCT00400387Phase 3Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- Nov 2006
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of dalteparin in recurrent pregnancy loss (RPL) (2 arms), sponsored by Friedrich Schiller University Jena. Primary endpoint: ongoing intact pregnancy at 24 weeks of gestation. Started Nov 2006; status: completed.
02
Drugs
dalteparin
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT00400387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400387.